T A B L E O F C O N T E N

S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
LAM A add-on compared with ICS alone for adults with asthma ⊕⊕ Low c,f * The basis f or the assumed risk (e.g. m edian control group risk across studies) is provided in f ootnotes. The corresponding risk (and its 95% conf idence interval) is based on the assum ed risk in the com parison group and the relative effect of the intervention (and its 95% CI). †Only pooled data f rom the twin trials were available f or this outcom e and had to be entered under one study ID. ACQ: Asthm a Control Questionnaire; AEs: adverse events; AQLQ: Asthm a Quality of Lif e Questionnaire; CI: conf idence interval; FEV 1 : f orced expiratory volum e in 1 second; ICS: inhaled corticosteroid; LAM A: long-acting m uscarinic antagonist; M CID: m inim al clinically im portant dif f erence; OCS: oral corticosteroid.
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the estim ate of ef f ect. M oderate quality: Further research is likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and m ay change the estim ate. Low quality: Further research is very likely to have an im portant im pact on our conf idence in the estim ate of ef f ect and is likely to change the estim ate. Very low quality: We are very uncertain about the estim ate.
a Conf idence interval does not exclude the possibility of benef it f rom ICS alone, but both conf idence lim its are well below the established M CID of 0.5 on these scales (no downgrade). b I 2 = 59%, P value = 0.05 (-1 inconsistency). c One study in this analysis allowed participants to continue taking com bination ICS/ LABA; theref ore, som e results were derived f rom participants who do not m eet all inclusion criteria f or this review. The study accounted f or a m axim um of 26.7% of the analysis weight, and m ostly less than 20% (-1 indirectness). d Som e statistical heterogeneity but not statistically signif icant (no downgrade). e I 2 = 72%, P value = 0.03 (-1 inconsistency). f Som e studies reported ''adverse events (all)'' as those not classed as serious; theref ore, this f igure taken alone m ay not equal adverse events of all severities. In addition, it was som etim es possible to extract adverse event (AE) data f rom clinicaltrials.gov only when AEs occurring in > 5% of participants were listed (-1 indirectness).
B A C K G R O U N D Description of the condition
Asthma is a "heterogeneous disease, usually characterised by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness, and cough that vary over time and in intensity, together with variable expiratory airflow limitation" (GINA 2014b) . Common triggers include allergens, pollutants and viral infections, although endogenous factors have also been identified. The World Health Organization (WHO) recognises the global burden of asthma and estimates a worldwide prevalence of 300 million people of all ages, with 250,000 people dying each year (WHO 2007) . Asthma prevalence is greater in urbanised communities, and with the world's urbanised population projected to grow from 45% to 59% by 2025, the number of people diagnosed with asthma is predicted to increase by 100 million over this time (Global Burden of Asthma Report 2004) . Epidemiological data suggest that prevalence is greatest in the developed world, with prevalence amongst adults at 8.2% in the USA (CDC 2014) and at 9% to 10% in the UK (DOH 2012) . Asthma presents a heavy financial burden on health services in the UK and worldwide (Global Asthma Report 2011) , with the National Health Service (NHS) spending a billion pounds per year on treatment of patients with asthma (Asthma UK 2014). This considerable expense represents direct medical costs, such as provision of medicines and frequent general practitioner (GP) consultations, outpatient services and hospital admissions due to poorly controlled disease (Barnes 1996) . However, the economic cost of asthma is worsened by indirect costs to the patient resulting from time off work or school due to sickness and loss of earnings due to morbidity and early mortality (Global Burden of Asthma Report 2004) . Asthma can present with varying degrees of severity; in the most severe cases, it can cause daily chronic symptoms and frequent exacerbations (defined as acute worsening of asthma symptoms). Overarching principles of treatment focus on controlling daily symptoms and preventing exacerbations. Bronchodilating agents and corticosteroids delivered via inhaler devices are the mainstay in asthma management. Short-acting bronchodilating agents such as salbutamol are used on a "when required" basis as reliever therapy, and inhaled corticosteroids (ICSs) are given regularly as maintenance therapy. Other agents employed in asthma management include inhaled long-acting bronchodilating beta 2 -agonists (LABA) and leukotriene-receptor antagonists (taken as tablets). Treatment is introduced and is increased through a step-wise approach, depending on the severity and frequency of symptoms (BTS/SIGN 2012; GINA 2014a).
Description of the intervention
Asthma treatment is commenced at the level most likely to achieve control of the patient's symptoms; treatment is stepped up to maintain this control and is stepped down when the patient's condition is stable and has been well maintained (BTS/SIGN 2012; GINA 2014a) .
Step 1 involves the use of a short-acting bronchodilating agent alone on a when-required basis; patients who remain inadequately controlled are increased to step 2, with the introduction of an inhaled corticosteroid (ICS) for regular use as maintenance therapy. Regular daily therapy with an ICS is known to improve lung function and symptom control while reducing airway inflammation and use of reliever therapy compared with intermittent use of an ICS (Chauhan 2013). However, if regular use of an ICS at a low to medium dose does not maintain control of the patient's symptoms-that is, the patient suffers from recurrent exacerbations or nocturnal awakening, or frequently uses reliever therapy to relieve symptoms of breathlessness, chest tightness and wheeze-a step up in treatment to step 3 is required. At step 3 in the management guidelines, the addition of a long-acting beta 2 -agonist (LABA) is recommended for adults, as this was found to be superior to alternative treatments (Chauhan 2014 : Ducharme 2010 . Alternative therapies for people whose asthma is not well controlled on low to medium doses of ICS and for whom a LABA has not worked include introducing a daily leukotriene receptor antagonist tablet or increasing the ICS dose (BTS/SIGN 2012; GINA 2014a). Long-acting muscarinic antagonists (LAMAs) are not currently recommended in evidence-based guidelines for the treatment of patients with asthma; only one LAMA preparation (Spiriva Respimat 2.5 mcg) has had its licence extended for use in people with asthma, and only for patients already taking combination LABA and ICS who have had at least one severe exacerbation in the previous year (eMC 2014a). However, several other LAMA preparations are used frequently for the treatment of chronic obstructive pulmonary disease (COPD). COPD, like asthma, is characterised in part by airway obstruction, and patients benefit from the bronchodilating effects of LAMA, which reduce airflow limitation and improve symptoms (NICE 2010) . Previous studies have demonstrated that the LAMA tiotropium significantly reduced the frequency of exacerbations and hospital admissions related to COPD, and improved lung function and quality of life in patients with COPD (Karner 2014).
How the intervention might work
Long-acting muscarinic antagonists act by inhibiting the effects of acetylcholine at muscarinic (M)-receptors. When administered via inhalation, they competitively antagonise M 3 -receptors, preventing acetylcholine-mediated constriction of bronchial smooth muscle. This permits dilation of the airways. Their slow dissociation from local M 3 -receptors and prolonged half-lives mean that such agents are administered only once or twice daily (EMC 2013a; EMC 2013b; EMC 2014b) .
Chronic obstructive pulmonary disease and asthma share similar symptoms, namely, shortness of breath, chronic cough and wheeze (BTS/SIGN 2012; NICE 2010) . Regulation of airway smooth muscle tone by M-receptors is enhanced and contributes to airflow obstruction in both COPD and asthma (Gosens 2006) . Therefore, a reduction in M-receptor-mediated airway constriction would be beneficial in relieving these common symptoms of COPD and asthma. Previous studies and national guidelines for COPD have shown that LAMA and LABA have comparable efficacy in treating patients with moderate COPD (NICE 2010) . LABA is also a bronchodilator and is the favoured treatment for introduction at step 3 or 4 of asthma management, when it is administered concomitantly with an ICS to improve control of symptoms (GINA 2014a) . Although a LAMA mediates bronchial smooth muscle relaxation in a manner different from that of a LABA, its bronchodilatory effect may be beneficial for patients who require a step up in their asthma management when ICS alone is insufficient.
Why it is important to do this review
Although several evidence-based therapies and non-pharmacological strategies are available to improve control of symptoms and to prevent exacerbations of asthma, mortality due to asthma remains a risk for patients. Asthma UK reported 1167 deaths due to asthma in 2011, while "75% of hospital admissions for asthma are avoidable and as many as 90% of the deaths from asthma are preventable" (Asthma UK 2014). This highlights the fact that current management of asthma remains suboptimal and indicates that development of new management strategies and treatments would be beneficial. As a result of the common features of COPD and asthma-such as up-regulation of M-receptor-mediated airway tone and subsequent symptoms of breathlessness, cough and wheeze-known benefits of inhaled LAMA in COPD may also be beneficial for patients with asthma, particularly those with severe asthma whose condition remains inadequately controlled by current recommended step 3 therapy. Previous trials have demonstrated the potentially beneficial effects of the LAMA tiotropium on lung function in patients with asthma (Peters 2010; Vogelberg 2014). However, a definitive conclusion on the benefit of LAMA in asthma is lacking, as is information explaining where in the current step-wise management strategy they would be most beneficial. Therefore, a systematic review of all available randomised controlled trials on the addition of a LAMA to an ICS would be beneficial in revealing any benefit to be derived from the use of LAMA in asthma that remains uncontrolled by an ICS alone. Three associated reviews will assess the following.
• LAMA add-on compared with LABA add-on.
• LAMA add-on compared with increased ICS dose.
• LAMA add-on as triple therapy with LABA + ICS compared with LABA + ICS alone.
O B J E C T I V E S
To assess the efficacy and safety of a long-acting muscarinic antagonist (LAMA) added to any dose of an inhaled corticosteroid (ICS) compared with the same dose of ICS alone for adults whose asthma is not well controlled.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included parallel and cross-over randomised controlled trials (RCTs) of at least 12 weeks' duration reported as full text, those published as abstract only and those with unpublished data. We did not exclude studies on the basis of blinding.
Types of participants
We included adults (aged 18 years or older) whose asthma was not well controlled by ICS alone. We excluded trials that included participants with chronic respiratory co-morbidities (e.g. COPD, bronchiectasis). If studies included adults and adolescents or children younger than 12 years and data are not reported separately, we included them if the mean age in both groups was over 18 years.
Types of interventions
We included trials comparing a LAMA added to any dose of ICS therapy versus continued use of ICS at the same dose. This meant that studies in which participants were randomly assigned to LAMA or placebo, with inclusion criteria specifying that participants should be taking a stable dose of background ICS, were included. We included studies that permitted the use of shortacting medications (e.g. salbutamol, terbutaline, ipratropium) as reliever therapy. We excluded trials in which a LABA was given as part of the randomly assigned treatment and those in which most participants continued their LABA alongside the randomly assigned treatment. Studies involving the addition of any of the following LAMA preparations were included.
• Tiotropium (Spiriva Handihaler or Respimat).
• Aclidinium bromide (Eklira Genuair).
• Glycopyrronium bromide (Seebri Breezhaler). 
Types of outcome measures Primary outcomes
• Exacerbations requiring oral corticosteroids.
• Quality of life (measured on a validated asthma scale, e.g. Asthma Quality of Life Questionnaire).
• All-cause serious adverse events.
Secondary outcomes
• Exacerbations requiring hospitalisation.
• Lung function (in particular, trough forced expiratory volume in one second (FEV 1 )).
• Asthma control (as measured on a validated scale, e.g. Asthma Control Questionnaire, Asthma Control Test).
• Any adverse events.
Reporting by trial authors of one or more of the outcomes listed here was not an inclusion criterion for the review. If exacerbations were reported as a composite of more than one definition (e.g. study participants with one or more exacerbations requiring hospitalisation or an emergency department (ED) visit), we analysed these separately.
Search methods for identification of studies Electronic searches
We identified trials from the Cochrane Airways Group Specialised Register (CAGR), which is maintained by the Trials Search Coordinator for the Group. This Register contains trial reports identified through systematic searches of bibliographic databases, including the Cochrane Central Register of Controlled Trials (CEN-TRAL), MEDLINE, EMBASE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Allied and Complementary Medicine Database (AMED) and PsycINFO, and by handsearching of respiratory journals and meeting abstracts (please see Appendix 1 for further details). We searched all records in the CAGR using the search strategy provided in Appendix 2. We also conducted a search of ClinicalTrials.gov (www.ClinicalTrials.gov) and the World Health Organization (WHO) trials portal (www.who.int/ictrp/en/). We searched all databases from their inception to the present, and we imposed no restriction on language of publication.
Searching other resources
We checked the reference lists of all primary studies and review articles to look for additional references. We searched relevant manufacturers' websites for trials and other information.
We searched for errata or retractions from included studies published in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed) on 9 April 2015.
Data collection and analysis
Selection of studies
Using Covidence, two review authors (DA and KK) independently screened titles and abstracts for inclusion of all potential studies identified as a result of the search. We retrieved the full-text study reports/publications; two review authors (DA and KK) independently screened the full-text reports to identify studies for inclusion, and identified and recorded reasons for exclusion of ineligible studies. We will resolve disagreements through discussion or, if required, by consultation with a third person. We identified and excluded duplicates and collated multiple reports on the same study, so that each study rather than each report was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram and a Characteristics of excluded studies table.
Data extraction and management
We used a data collection form in Covidence that had been piloted on at least one study in the review to document study characteristics and outcome data. Both review authors (DA and KK) extracted the following study characteristics from included studies.
• Methods: study design, total duration of study, details of any 'run-in' period, number of study centres and locations, study settings, withdrawals and dates of study.
• Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria and exclusion criteria.
• Interventions: interventions, comparisons, concomitant medications and excluded medications.
• Outcomes: primary and secondary outcomes specified and collected and time points reported.
• Notes: funding for trial and notable conflicts of interest of trial authors.
Two review authors (DA and KK) independently extracted outcome data from included studies. We noted in the Characteristics of included studies table if outcome data were not reported in a useable way, and we resolved disagreements by discussion. One review author (KK) transferred data into the Review Manager (Review Manager 2014 (RevMan)) file. We double-checked that data had been entered correctly by comparing data presented in the systematic review versus those provided in study reports.
Assessment of risk of bias in included studies
Two review authors (DA and KK) independently assessed risk of bias for each study, using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We resolved disagreements by discussion and assessed risk of bias according to the following domains.
• Random sequence generation.
• Allocation concealment.
• Blinding of participants and personnel.
• Blinding of outcome assessment.
• Incomplete outcome data.
• Selective outcome reporting.
• Other bias.
We graded each potential source of bias as high, low or unclear and provided a quote from the study report together with a justification for our judgement in the Risk of bias in included studies table.
We summarised risk of bias judgements across different studies for each of the domains listed and considered blinding separately for different key outcomes when necessary (e.g. for unblinded outcome assessment, risk of bias for all-cause mortality may be very different than for a patient-reported pain scale). When information on risk of bias was related to unpublished data or correspondence with a trial author, we noted this in the Risk of bias in included studies table.
In cases for which the method of random sequence generation or allocation concealment was not adequately described, but the study was funded by a manufacturer with whom methods had previously been confirmed, we assumed that the same methods were applied. In the event of such insufficient reporting, we contacted the study author or sponsor to ask for additional information to clarify uncertainties and to support our assumption that the same methods were applied. When considering treatment effects, we took into account the risk of bias for studies that contributed to that outcome.
Assessment of bias in conducting the systematic review
We conducted the review according to this published protocol and reported deviations from it in the Differences between protocol and review section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as odds ratios, and continuous data as mean differences or standardised mean differences. We entered presented data as a scale with a consistent direction of effect. We narratively described skewed data reported as medians and interquartile ranges. When both raw data and adjusted analyses (e.g. accounting for baseline differences) were presented, we used the latter. When data published in peer-reviewed papers was different from those given on clinicaltrials.gov, we cross-checked them (using generic inverse vairience (GIV) and RevMan analyses when only mean difference vs placebo was available), and we contacted study sponsor or trial authors to ask for more information if we noted discrepancies in effects. We undertook meta-analyses only when this was meaningful (i.e. when treatments, participants and the underlying clinical question were similar enough for pooling to make sense). When multiple trial arms were reported in a single trial, we included only the relevant arms. When two comparisons (e.g. drug A vs placebo and drug B vs placebo) were combined in the same meta-analysis, we halved the control group to avoid double counting. When both change from baseline and endpoint scores were available for continuous data, we used change from baseline unless most studies reported endpoint scores. If a study reported outcomes at multiple time points, we used the end-of-study measurement.
When both an analysis using only participants who completed the trial and an analysis that imputed data for participants who were randomly assigned but did not provide endpoint data (e.g. last observation carried forward) were available, we used the latter. For dichotomous outcomes, we assumed equivalence of treatments if the odds ratio estimate and its 95% confidence interval were between the pre-defined arbitrary limits of 0.9 and 1.1.
Unit of analysis issues
For dichotomous outcomes, we used participants rather than events as the unit of analysis (i.e. number of adults admitted to hospital rather than number of admissions per adult).
Dealing with missing data
We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data when possible (e.g. when a study was identified as an abstract only). When this was not possible, and when missing data were thought to introduce serious bias, we performed a sensitivity analysis to explore the impact of including such studies in the overall assessment of results.
Assessment of heterogeneity
We used the I² statistic to measure heterogeneity among the trials in each analysis. If we identified substantial heterogeneity (e.g. I 2 > 30%), we reported this and explored possible causes through pre-specified subgroup analyses.
Assessment of reporting biases
We were not able to pool more than 10 trials, so we could not examine a funnel plot to explore possible small-study and publication biases.
Data synthesis
We used a random-effects model for all analyses, as we expected variation in effects due to differences in study populations and methods. We performed sensitivity analyses using fixed-effect models.
'Summary of findings' table
We created Summary of findings for the main comparison to document all primary and secondary outcomes listed in the protocol. We used the five GRADE (Grades of Recommendation, Assessment, Development and Evaluation) considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of a body of evidence as it relates to studies that contributed data to the meta-analyses for prespecified outcomes. We applied methods and recommendations as described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011) using GRADEpro software (Brozek 2008) . We justified all decisions to downgrade or upgrade the quality of studies by using footnotes and by making comments when necessary to aid the reader's understanding of the review.
Subgroup analysis and investigation of heterogeneity
We planned the following subgroup analyses for primary outcomes.
• Duration of therapy (≤ 6 months, > 6 months).
• Corticosteroid dose (according to GINA 2014, defined as low, medium and high cutoffs).
• Dose and type of LAMA (e.g. tiotropium HandiHaler 18 mcg, tiotropium Respimat 5 mcg).
We used the formal test for subgroup interactions provided in Review Manager 2014 (RevMan).
Sensitivity analysis
We planned the following sensitivity analyses on primary outcomes, with the following studies excluded.
• Unpublished data.
• Studies at high risk of bias for blinding (participants and personnel).
We conducted an unplanned sensitivity analysis on primary outcomes by removing one study in which around half of the participants were taking a LABA, which was outside the inclusion criteria.
R E S U L T S Description of studies
Results of the search
We identified 71 records through electronic database searches and obtained a further 122 records from additional resources (clinicaltrials.gov, reference lists of other publications and drug company trial registries). Of the total 193, we identified 54 as duplicates and screened the remaining 139. Upon screening titles and abstracts, we excluded 105 that did not meet the inclusion criteria. We excluded 22 of the remaining 34 records after retrieving and inspecting full texts; these related to 20 studies. The main reasons for exclusion were as follows: LABA were part of the randomly assigned treatment (n = 6), the study was too short (n = 6) and the wrong comparator was used (n = 5). The remaining 12 records related to five studies that met all inclusion criteria and were included in the qualitative synthesis. All five studies reported data that could be included in at least one meta-analysis. Trial flow is shown in Figure 1 .
Included studies Design and duration
We identified five studies that made the comparison of interest and met the inclusion criteria. Details of study characteristics are provided in Characteristics of included studies and in Table 1 . All studies were of a double-blind, double-dummy design, and the population for all studies totalled 2563 adult participants. Duration of studies ranged from 12 weeks to 52 weeks. Only the LAMA plus ICS and placebo (ICS-only) groups in each study are relevant to the present review and are considered herein. The LABA plus ICS groups featured in NCT00350207, NCT01172821 and NCT01172808 are considered in a related systematic review (see Kew 2015) . When further clarification of study design or outcome analyses was required, we contacted study authors, who were able to provide additional information and analyses.
Participant inclusion and exclusion criteria
Included participants were between 18 and 75 years of age at the start of the study and had a three-month history of asthma, which was first diagnosed before the age of 40. Included participants were symptomatic despite their current maintenance therapy, which they had been using for at least four weeks before the trials began. Participants included in the studies were able to correctly use all inhaler devices randomly assigned to them and were able to carry out all tests and procedures related to collating outcome measures. Patients with a concomitant "significant disease" were excluded from the study. This was defined by Boehringer Ingelheim as a "disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the trial, or (ii) influence the results of the trial, or (iii) cause concern regarding the patient's ability to participate in the trial; patients with a clinically relevant abnormal screening (visit 1) haematology or blood chemistry if the abnormality defines a significant disease as defined in exclusion criterion no. 1". Patients with very unstable asthma and requiring in excess of 10 puffs of reliever therapy per day on two consecutive days during the screening period were also excluded from the trials, as were those with concomitant lung disease, arrhythmia or recent history of heart failure or acute coronary disease (within the previous 12 months and 6 months, respectively). Smokers and exsmokers who had stopped smoking the year before the trial commenced were also excluded from the studies.
Participant baseline characteristics
The mean age of participants and the proportion of males and females in each study group were reported in all five included studies. The mean ages of participants were between 41 and 48 years. The percentage of male participants remained consistently less than half of the study population and ranged from 33.3% to 46.8%. The mean percentage predicted FEV 1 at baseline was between 72% and 75% in three studies reporting pre-bronchodilator values, and 91% and 94% across groups in the only study reporting post-bronchodilator values (NCT01316380). Participants had a long history of asthma, and the mean number of years since diagnosis ranged from 16 to 23 across groups in the four studies reporting this measure.
Characteristics of the interventions
All of the studies included in this review compared the use of tiotropium in addition to the pre-study ICS medication versus the use of pre-study ICS medication alone. All studies included tiotropium at a dose of 5 mcg daily, and four of the five studies were multi-arm trials that included separate arms receiving 2.5 mcg (low-dose) and 5 mcg (high-dose) of tiotropium daily (NCT01172808; NCT01172821; NCT01316380; NCT01340209). All studies delivered tiotropium via a Respimat inhaler. Matching placebo Respimat inhalers were provided to participants randomly assigned to the placebo group. Inhaled corticosteroids were not included as part of the randomly assigned treatment but were specified as part of the inclusion criteria of all studies. Inclusion criteria for NCT00350207 included treatment with 400 to 1000 mcg of budesonide or equivalent. One study included only participants with at least a four-week history of treatment with a low, stable dose of ICS (NCT01316380). Remaining studies required at least a fourweek history of treatment with a medium, stable dose of ICS (NCT01172808; NCT01172821; NCT01340209). However, in NCT01340209, participants were included if they took ICS alone or in fixed combination with a LABA. We included this study because participants were not required to be taking the ICS/LABA combination to be included in the trial, and the split between those taking ICS alone (43%) and those given ICS alongside a LABA (57%) was relatively even. Sensitivity analyses were performed to remove this study from the primary outcomes. Participants in all studies continued this usual maintenance dose of ICS throughout the study period, including those taking LABA alongside ICS in fixed combination in NCT01340209. The actual ICS taken by participants per day was not available in most studies. All studies permitted the use of rescue beta-agonist medication during the study period.
Excluded studies
After viewing full texts, we excluded 13 studies. The main reasons for exclusion included use of a LABA as part of the randomly assigned treatment and the requirement that participants take ICS/ LABA combination therapy if they were to be included in the trial (n = 4 records, relevant to a separate review (Kew 2015)). Four records were excluded because they used a comparator not relevant to this review. Other reasons for exclusion were these: study duration too short (i.e. duration < 12 weeks; n = 3 records), wrong intervention used (n = 1 record) and wrong population examined (n = 1 record). Excluded studies and reasons for exclusion are listed in Characteristics of excluded studies.
Risk of bias in included studies
Overall, included studies showed high methodological quality and were largely given low risk of bias ratings (Figure 2 ). When insufficient information was available in published and publicly available isources, we contacted the trial authors to ask for clarification of methods used.
Allocation
Information within the clinicaltrials.gov records or published reports was generally insufficient to warrant low risk of bias ratings, but prior contact with study sponsors and additional contact for this review confirmed that standard practices were applied by study sponsors (who used computerised codes and automated allocation systems). For this reason, we judged all included studies to be at low risk of selection bias.
Blinding
We rated all studies as having low risk of bias for blinding of participants, personnel and outcome assessors. All studies were designed to be double-blind and double-dummy, with the use of matching placebo inhalers.
Incomplete outcome data
We rated all studies as having low risk of bias due to attrition. Participant dropout was less than 10% in all groups within the included studies. Investigators reported he numbers of participants who were randomly assigned to a study arm but did not complete the study, as well as the numbers of participants who provided data for all outcome measures. They also provided reasons for noncompletion of the study.
Selective reporting
We originally rated two of the included studies as having high risk of bias for selective reporting (NCT01172808, NCT01172821) because the number of participants in each group who had an exacerbation of asthma was not given, even though this was listed as a secondary outcome measure. It was suggested that this was done because "less than 50% of participants in each treatment group experienced an asthma exacerbation". Also in relation to "all adverse events" reported by these two studies, researchers reported only adverse events experienced by at least 5% of the study population, which led to an apparent underestimation of the magnitude of all adverse events experienced. Both of these issues were resolved when the full text was published in a peer-reviewed journal, so we assessed all studies as having low risk of bias for selective reporting.
Other potential sources of bias
We deemed one study to have unclear risk of bias due to another potential source. This involved an imbalance in the number of participants in each study arm who had never smoked and was considered to present potential risk for study outcomes. We noted no issues with the other four studies and consequently rated them as having low risk of bias.
Effects of interventions
See: Summary of findings for the main comparison LAMA add-on compared with ICS alone for adults with asthma
Primary outcomes
Exacerbations requiring oral corticosteroids LAMA reduced the odds that participants would need to take oral corticosteroids (OCS) for an exacerbation of asthma compared with those for ICS alone (odds ratio (OR) 0.65, 95% confidence interval (CI) 0.46 to 0.93; participants = 2277; four studies; I 2 = 0%). As shown in Figure 3 , this means that 27 fewer people per 1000 would require an OCS for an exacerbation longer than 21 weeks if they took a LAMA rather than an ICS alone (95% CI 42 fewer to 6 fewer). Data for the twin trials (NCT01172808 and NCT01172821) were available only as a pooled result, so they had to be entered as one study. We rated the evidence as high quality. As a supplementary post hoc analysis, we looked at events coded as 'asthma' in the non-serious adverse events tables using Med-DRA (Medical Dictionary for Regulatory Activities) terminology.. The sort of asthma events that would have been counted under this term is not clear, so findings are difficult to interpret, but all studies reported data in this way. Fewer 'adverse events classified as asthma' were reported for groups taking LAMA than for those who did not, although the confidence interval showed no difference (OR 0.85, 95% CI 0.69 to 1.05; participants = 2561; five studies; I 2 = 0%). Risk of bias assessments and unpublished data sensitivity analyses were not necessary, but we performed a sensitivity analysis after removing NCT01340209 -the study in which some participants continued to take a long-acting beta 2 -agonist -and found that results were largely similar (OR 0.87, 95% CI 0.70 to 1.10; participants 2276; four studies; I 2 = 0%). We graded the quality of evidence for this analysis as low after downgrading, because only a small population contributed data to this analysis, only two of the five included studies measured this outcome and poor definitions were provided for exacerbations requiring OCS in each of these studies.
Quality of life
Scores on the Asthma Quality of Life Questionnaire (AQLQ) were slightly higher for those taking a LAMA than for those continuing on ICS alone, but confidence intervals showed benefit for both treatments and were not within the range of the scale's established minimal clinically important difference (MCID) of 0.5 (MD 0.05, 95% CI -0.03 to 0.12; participants = 1713; three studies; I 2 = 0%). None of the planned sensitivity analyses could be performed on this outcome (no studies at high risk of bias, no unpublished data and no outcomes reported by the partial ICS/LABA study (NCT01340209)). We graded evidence for this outcome as high in quality.
All-cause serious adverse events
People in these studies who were taking LAMA reported fewer serious adverse events, but the pooled effect was too inconsistent and imprecise to suggest a definitive benefit over ICS alone (OR 0.60, 95% CI 0.23 to 1.57; participants = 2562; five studies; I 2 = 59%). Given the heterogeneity, we performed a sensitivity analysis using a fixed-effect model, which increased the precision of the estimate, suggesting fewer serious adverse events in people taking LAMA add-on. As with exacerbations requiring OCS, we performed a sensitivity analysis after removing NCT01340209; the magnitude of the effect was reduced, as was heterogeneity, but it remained similarly imprecise (OR 0.87, 95% CI 0.37 to 2.05; participants = 2277; five studies; I 2 = 27%). This outcome was downgraded to low quality as the result of heterogeneity and inclusion in NCT01340209 of some participants taking a LABA.
Secondary outcomes Exacerbations requiring hospitalisation
A total of nine people required hospital admission for an asthma exacerbation during study periods, which meant that the estimate was imprecise because few events were reported (OR 0.42, 95% CI 0.12 to 1.47; participants = 2562; five studies; I 2 = 0%). The effect included no benefit due to this imprecision but fewer hospital admissions with LAMA add-on. We also downgraded this outcome because some participants in NCT01340209 did not meet the inclusion criteria.
Lung function
Forced expiratory volume in one second (FEV 1 )
Trough FEV 1 measurements improved by an additional 140 mL in people taking LAMA add-on compared with those given ICS alone (mean difference (MD) 0.14 mL, 95% CI 0.10 to 0.17; participants = 2459; five studies; I 2 = 26%). People who had been taking LAMA add-on also had much improved peak FEV 1 measurements (MD 0.19 L, 95% CI 0.15 to 0.23; participants = 1923; three studies; I 2 = 39%). Both analyses showed a degree of inconsistency between study results, but this finding was not statistically significant. We rated the evidence for this outcome as high in quality.
Peak expiratory flow (PEF)
Trough measurement of PEF was almost 30 L/min better in people taking LAMA add-on (MD 28.07 L/min, 95% CI 22.51 to 33.64; participants = 2456; five studies; I 2 = 24%), and again some heterogeneity between study results was evident.
Forced vital capacity (FVC)
People taking a LAMA showed trough FVC improvements 90 mL greater than those found in people not taking a LAMA (MD 0.09, 95% CI 0.05 to 0.13; participants = 2002; four studies; I 2 = 8%), and the result for peak measurements was of similar magnitude and precision (MD 0.11, 95% CI 0.08 to 0.15; participants = 1922; three studies; I 2 = 6%). Both analyses revealed a small amount of statistical heterogeneity.
Asthma control
Participants taking LAMA add-on improved slightly more on the Asthma Control Questionnaire (ACQ) than those taking ICS alone, but confidence intervals for the effect showed no difference and heterogeneity was significant (MD -0.08, 95% CI -0.19 to 0.03; participants = 1916; three studies; I 2 = 72%). Results and confidence intervals also fall well below the scale's MCID of 0.5. We downgraded to moderate the quality of the evidence used to assess differences in ACQ scores because results were inconsistent. The same studies and one other reported the number of people who improved by at least the MCID (ACQ 'responders'). Using this dichotomy, people in the LAMA group were more likely to 'respond' than those taking continued ICS, but the confidence intervals did not rule out the possibility that ICS alone was better, and significant variation between studies was noted (OR 1.23, 95% CI 0.87 to 1.74; participants = 2009; three studies; I 2 = 69%).
Any adverse events
People taking LAMA add-on did not have a significantly different number of adverse events of any kind compared with those given ICS alone (OR 0.95, 95% CI 0.80 to 1.14; participants = 2562; five studies; I 2 = 0%). This outcome was graded as low in quality because some participants were taking LABA in NCT01340209, and because some studies reported only adverse events that occurred in at least 5% of participants. 
Subgroup analyses Duration of therapy
All of the studies reporting exacerbations requiring OCS and the three studies reporting quality of life on the AQLQ were less than six months in duration, so it was not possible to perform a subgroup analysis by duration for these two primary outcomes. These outcomes also showed no important statistical heterogeneity, so it was not necessary to investigate effect modifiers. A subgroup analysis by study duration for the remaining primary outcome -all-cause serious adverse events -showed a significant difference between the pooled result for the four shorter trials and the one-year-long trial (I 2 = 80%; P value = 0.03). This must be interpreted with caution because of the observational nature of subgroup analyses, and because only one trial was included in one of the subgroups.
Corticosteroid dose
No statistical heterogeneity was noted between studies reporting exacerbations requiring OCS, so comparisons in a steroid dose subgroup analysis were meaningless. The three studies reporting quality of life on the AQLQ used medium doses of inhaled steroids, so no comparison could be made. We split studies reporting the remaining primary outcome -allcause serious adverse events -into low-dose (NCT01316380) and medium-dose (NCT00350207; NCT01172808; NCT01172821; NCT01340209) subgroups. NCT00350207 allowed doses up to 1000 mcg budesonide equivalent (high dose), but these were classified as medium dose, as more of the range fell under the medium dose category (400 to 800 mcg). Heterogeneity within the outcome was not accounted for by differences in ICS dose (heterogeneity within the medium-dose subgroup remained significant).
Dose and type of LAMA
All included studies used tiotropium Respimat as their LAMA, and all but one study included two dose groups that were merged in the main comparison. To compare these, we separated out the dose groups and compared them against the same control group, while adjusting for double counting in each analysis. Tests for subgroup differences did not suggest differences between the two doses for any of the primary outcomes (Analysis 2.2). In addition to the planned subgroup analysis, we performed a direct comparison of the two doses using the four studies in which this was possible (all but NCT00350207). The effect estimate was too imprecise for review authors to conclude whether one dose was better than another for reducing exacerbations requiring OCS (Analysis 3.1). Direct dose comparisons for quality of life on the AQLQ (Analysis 3.2) and for all-cause serious adverse events (Analysis 3.3) did not suggest differences in effect for the two doses.
Sensitivity analyses Studies at high risk of bias for blinding of participants and personnel
We rated none of the studies as having high risk of bias for blinding.
Unpublished data (i.e. no peer-reviewed full paper available)
No conference abstracts were included, and all data included in the primary outcomes were available in peer-reviewed reports or on publicly available websites.
D I S C U S S I O N
Summary of main results
Five studies met the inclusion criteria; all were double-blind, double-dummy randomised controlled trials and ranged in length from 12 to 52 weeks. We included in this review data from 2563 participants; we conducted this review to compare the use of inhaled corticosteroid (ICS) only versus tiotropium (LAMA) 2.5 mcg or 5 mcg daily in addition to ICS therapy. Participants in all included studies continued their pre-study maintenance dose of ICS throughout the study period, which ranged from low dose to high dose. More women than men were included in the trials (33% to 47% male), and mean age of participants ranged from 41 to 48 years. Participants generally had a long history of asthma, and mean baseline percentage predicted FEV 1 was between 72% and 75% in three studies reporting pre-bronchodilator values. All studies reported good methods and were considered to be at low risk of bias for most of the assessed domains (Figure 2) . High-quality evidence shows that the rate of exacerbations requiring oral corticosteroids (OCS) was significantly lower in patients prescribed a LAMA add-on (27 fewer per 1000 participants, 95% CI 6 fewer to 42 fewer) than in those receiving the same dose of ICS alone. Similarly, four fewer people per 1000 participants would have an exacerbation resulting in hospitalisation if prescribed a LAMA add-on compared with the same dose of ICS alone; this result was not statistically significant, with a confidence interval ranging from five fewer to three more people (per 1000) having such an exacerbation. Eleven fewer people (per 1000) would experience a serious adverse event when receiving a LAMA add-on; however, the confidence interval ranged from 22 fewer people to 16 more people experiencing a serious adverse event with the addition of LAMA therapy and highlighted the imprecision of this result. Such events were relatively rare among the study population; this may have been exacerbated by the short study period described in four of the five included studies (< six months). The addition of LAMA therapy did not show clear benefit for quality of life compared with ICS alone; high-quality evidence of only a small mean increase in quality of life score (AQLQ) was not statistically significant. The same was true for asthma control as measured on the ACQ, which was based on evidence of moderate quality. Addition of a LAMA led to significant improvement in lung function compared with the same dose of ICS alone, with FEV 1 increased by 0.14 L. Evidence used to evaluate this outcome was graded as high, despite slight heterogeneity and inclusion of data from only one study, which also recruited patients who were using a stable maintenance dose of LABA with ICS and permitted its use throughout the study period. LAMA was not associated with significantly higher rates of adverse events than were reported with placebo.
Overall completeness and applicability of evidence
The evidence base included in this review was lacking in several aspects. All included studies used tiotropium at a dose of 5 mcg daily (licensed dose) or 2.5 mcg daily; therefore, we cannot determine whether the results of this study apply to all other LAMA agents, such as glycopyrronium or aclidinium bromide, which, although not currently indicated for asthma, may be used to treat patients with asthma in the future. Included studies were designed to compare LAMA versus placebo, both combined with the usual ICS dose, but did not detail which ICS participants had used. Therefore, we cannot determine if the results of this study are affected by ICS choice. Study populations included participants using low, medium and high doses of ICS. Therefore, we cannot disregard the fact that this variation in ICS dose may have contributed to observed analyses, although the proportions of particpants using low, medium and high doses of ICS were consistent in both study arms. All studies included in this review were industry-sponsored trials that were conducted to a very high standard and in a controlled manner. However, this scenario may not truly reflect normal practice, for example, in relation to patient concordance with therapy, which may vary widely in general practice. This study analysed the effects of LAMA add-on therapy on the frequency of all-cause serious adverse events and exacerbations resulting in hospital admission. Such events were relatively rare in the study populations, and no significant reduction in the frequency of these outcome measures was found. This may reflect inclusion only of patients at step 2 of asthma management (BTS/SIGN 2012), whose disease was not so severe that exacerbations often resulted in hospital admission; however, the low frequency of such events may have been exacerbated by the relatively short duration of the included studies. The benefit of LAMA add-on in reducing all-cause serious adverse events was more pronounced in the only included study lasting longer than six months; therefore, future studies assessing these outcome measures in a similar population would benefit from longer trial duration for more accurate assessment of the effects of LAMA add-on therapy. Use of LAMA in the management of asthma is relatively new, with only one UK license extension granted for Spiriva Respimat. The licensed indication is only for use as triple therapy for patients already receiving maintenance therapy with a LABA and 800 mcg of budesonide or equivalent, who have had a least one severe exacerbation in the previous year. This group of patients is different from those considered in this review, but the study of LAMA in patients with less severe asthma suggests that further license extensions may be forthcoming. We hope that future versions of this review will provide more powerful and applicable findings on the use of LAMA for patients with less severe asthma.
Quality of the evidence
We rated evidence for one of the primary outcome measuresexacerbations requiring treatment with OCS -as high in quality. Although we included only 137 events in the analysis, we did not consider the effect imprecise, and we included data for more than 2200 people from four multi-centre studies. We rated asthmarelated quality of life on the AQLQ as high. We downgraded evidence for all-cause serious adverse events to low quality as the result of inconsistency and indirectness, the latter because the study (NCT01340209) included participants using an ICS, as well as those using an ICS/LABA in a fixed combination, and did not present results separately for these two groups of patients. Thus, results from participants who did not meet the inclusion criteria for this review have been included and reduce the reliability of the results. This is also true for exacerbations resulting in hospitalisation, lung function and all adverse events. We downgraded the evidence for asthma control (ACQ total) to moderate because of significant inconsistency. We downgraded the quality of the analysis of all adverse events to low, in part because of indirectness of the trial, which included some participants taking LABA/ICS, and because some of the included trials were available only on clinicaltrials.gov, which lists only adverse events experienced by a minimum of 5% of the study population.
Potential biases in the review process
We conducted this review in accordance with the standards set by MECIR 2013 and in keeping with the protocol (Allison 2014). We have reported deviations from the protocol in the section titled Differences between protocol and review.
We conducted an additional sensitivity analysis to exclude one trial, which included participants taking a LABA in addition to a stable ICS dose before and during the study period. As definitions for reported adverse events related to asthma were lacking in these studies, along with details on whether such exacerbations required oral corticosteroids, we conducted an analysis of all adverse events due to asthma. A skilled information specialist conducted the main electronic searches; thus it is unlikely that any relevant, qualifying studies or trials have been overlooked for inclusion in this review. We supplemented the main searches with searches of other sources (pharmaceutical company clinical trial registries and reference lists of associated studies and reviews), in addition to those required by MECIR 2013 (i.e. clinicaltrials.gov, World Health Organization (WHO) trials portal). We attempted to contact the authors of any trials from which were we required additional data or clarification of methods.
Agreements and disagreements with other studies or reviews
Use of LAMA in the management of asthma has been reviewed in many studies. Timmer et al. found that tiotropium, at doses of 5 mcg daily or 2.5 mcg twice daily, resulted in significant improvement in all measures of lung function compared with placebo, when added to medium-dose ICS for patients with asthma, with a significant increase in adverse events (Timmer 2014) . This is consistent with the findings of other studies (Beeh 2014) and systematic reviews, some of which also highlighted the benefit of LAMA added on to other standard asthma treatments, such as ICS/LABA combination therapy, when the disease is inadequately controlled (Befekadu 2014; Rodrigo 2015; Tian 2014) . Rodrigo et al. identified that tiotropium add-on to ICS not only significantly improved lung function but also significantly reduced the rate of exacerbations and improved asthma control (Rodrigo 2015) . One study comparing the efficacy of tiotropium versus a LABA found that tiotropium at a dose of 18 mcg daily was comparable with salmeterol at a dose of 50 mcg twice daily when added to medium-dose ICS (Peters 2010) . This is consistent with findings of other systematic reviews and a related Cochrane review undertaken to assess the same hypothesis (Kew 2015; Rodrigo 2015) . This evidence supports the use of tiotropium as a bronchodilator in the management of asthma; however, further research is needed to determine the efficacy of other LAMA drugs, and oflong-term treatment, as most available evidence has been provided by studies four to 14 weeks in duration. The results of this review are not consistent with the evidence because these studies were only four weeks in duration, and data may reflect only temporary, shortterm improvement in symptoms associated with LAMA use; all studies included in this review have a minimum duration of 12 weeks, and results may highlight the fact that these short-term improvements in disease state are not maintained.
A U T H O R S ' C O N C L U S I O N S Implications for practice
For patients taking ICS without a LABA, LAMA used as addon therapy reduces the likelihood of exacerbations requiring treatment with OCS and improves lung function. Benefits of LAMA combined with ICS, including hospital admissions, all-cause serious adverse events, quality of life and asthma control, have not been ascertained.
Implications for research
Results of this review, along with those of related reviews assessing the use of LAMA in other clinical scenarios of asthma, will help to define the role of LAMA in the management of asthma. This review should be updated as results from ongoing trials are released. Trials of longer duration would provide better opportunities to observe rare events, such as serious adverse events and exacerbations requiring hospital admission.
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We acknowledge Elizabeth Stovold for designing the search strategy. 3) Inclusion criteria: patients homozygous for arginine at the 16th amino acid position of the beta 2 -adrenergic receptor (B16 Arg/Arg); informed consent form; male and female out-patients 18 to 65 years of age; documented history of asthma; current non-smokers or ex-smokers with a cigarette smoking history < 10 pack-years; maintenance treatment with inhaled corticosteroids with a total daily dose of 400 to 1000 mcg budesonide or equivalent Exclusion criteria: significant disease other than asthma; recent history (i.e. ≤ 6 months) of myocardial infarction; hospitalisation for heart failure within the past year; any unstable or life-threatening cardiac arrhythmia, or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year; malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the past 5 years (treated basal cell carcinoma allowed); COPD; history of life-threatening pulmonary obstruction, cystic fibrosis or bronchiectasis; known active TB; thoracotomy with pulmonary resection; current or recent (6 weeks) pulmonary rehabilitation
C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
NCT00350207
Methods
Interventions
Intervention characteristics LAMA add-on • ICS type/dose: 400 to 1000 mcg of budesonide/equivalent • Add-on type/dose: tiotropium 2 × 2.5 mcg daily in the evening (with salmeterolmatching placebo twice daily)
• Co-medications: ICS regimens were maintained throughout the trial. Concomitant respiratory medications were not allowed. Salbutamol metered-dose • ICS type/dose: 400 to 1000 mcg of budesonide/equivalent • Co-medications: ICS regimens were maintained throughout the trial. Concomitant respiratory medications were not allowed. Salbutamol metered-dose inhaler (100 mcg per puff ) as needed
• Type of inhaler: Respimat placebo (and MDI placebo to blind salmeterol arm)
• Duration of treatment: 16 weeks Participants were also randomly assigned to a third group, salmeterol add-on, which was not relevant to this review 20.2 (13.4) Inclusion criteria: informed consent; males and females 18 to 75 years of age; ≥ 3-month history of asthma at enrolment; diagnosis before 40.5 years of age, confirmed by FEV 1 increase ≥ 12% and ≥ 200 mL after salbutamol; on maintenance treatment with a medium, stable dose of ICS ≥ 4 weeks; ACQ (≥ 1.5) before randomisation; pre-bronchodilator FEV 1 60% to 90% of predicted normal at screening; variation in absolute FEV 1 at screening (pre-bronchodilator) as compared with visit 2 (pre-dose) within ± 30%; non-smoker ≥ 1 year with history < 10 pack-years; ability to use inhalers and perform trial procedures correctly Exclusion criteria: lung disease or significant medical illness other than asthma; clinically relevant abnormal screening, haematology or blood chemistry; hospitalisation for cardiac failure during the past year; any unstable or life-threatening cardiac arrhythmia; known active TB; resection, radiation or chemotherapy within 5 years for malignancy (treated basal cell carcinoma allowed); thoracotomy with pulmonary resection; significant alcohol or drug abuse within 2 years; current or recent (6 weeks) pulmonary rehabilitation; known hypersensitivity to study drugs or any other components of delivery systems; pregnant or nursing women; women of childbearing potential not using effective birth control; investigational drug, beta-blockers, tiotropium, oral or patch betaadrenergics, oral corticosteroids or "experimental" drugs for asthma not recommended by international guidelines within 4 weeks; anti-IgE antibodies, e.g. omalizumab, within 6 months; cromone, methylxanthines or PDE4 inhibitors within 2 weeks; asthma exacerbation or respiratory tract infection within 4 weeks; previous random assignment in this trial or in the respective twin trial (NCT01172821), or current participation in another trial
Intervention Characteristics LAMA add-on (low)
• ICS type/dose: Not part of randomised treatment, participants continued their medium dose of usual ICS
• Add-on type/dose: Tiotropium 2.5 mcg once daily (evening)
• Comedications: All, participants were taking maintenance treatment with a medium, stable dose of inhaled corticosteroids for at least 4 weeks prior to Visit 1
• Type of inhaler: Respimat (+ HFA MDI placebo twice daily to blind for salmeterol)
• Duration of treatment: 24 weeks LAMA add-on (high)
• Add-on type/dose: Tiotropium 5 mcg once daily (evening)
• Duration of treatment: 24 weeks Placebo (ICS alone)
• ICS type/dose: not part of randomly assigned treatment; participants continued their medium dose of usual ICS
• Co-medications: All; participants were taking maintenance treatment with a medium, stable dose of inhaled corticosteroids for ≥ 4 weeks before visit 1
• Type of inhaler: Respimat placebo (+ HFA MDI placebo to blind salmeterol arm)
• Duration of treatment: 24 weeks Participants were also randomly assigned to a fourth group, salmeterol add-on, which was not relevant to this review criteria: informed consent; males and females 18 to 75 years of age; ≥ 3-month history of asthma at enrolment; diagnosis of asthma before 40 years of age; pre-BD FEV 1 60% to 90% predicted normal at visit 1; variation in absolute pre-BD FEV 1 values at visit 1 vs visit 2 within ± 30%; diagnosis of asthma confirmed at visit 1 (or within 2 weeks) with bronchodilator reversibility (within 10 minutes before and 15 to 30 minutes after 400 µg salbutamol/albuterol), resulting in FEV 1 increase of 12% and 200 mL; symptomatic despite low doses of ICS; ACQ ≥ 1.5; low, stable ICS for ≥ 4 weeks before visit 1; never-smokers or ex-smokers ≥ 1 year and smoking history < 10 pack-years; ability to use Respimat inhaler correctly; ability to perform all trial-related procedures, including technically acceptable pulmonary function tests, and to use the e-Diary/peak flow meter (e-Diary-compliance ≥ 80% required); if relevant, continued use of allowed chronic pulmonary medication for entire duration of the study Exclusion criteria: lung or additional significant disease other than asthma, requiring more than 10 puffs of rescue medication (salbutamol/albuterol MDI) per 24 hours on 2 consecutive days during the screening period; acute coronary syndrome (STEMI, non-STEMI and unstable angina pectoris) within 6 months; hospitalisation for cardiac failure within 1 year; unstable or life-threatening cardiac arrhythmia, or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year; known active TB; malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within 5 years (treated basal cell carcinoma allowed); thoracotomy with pulmonary resection; significant alcohol or drug abuse within 2 years; current or recent (6 months) pulmonary rehabilitation; known hypersensitivity to anticholinergic drugs, BAC, EDTA or any other components of the tiotropium inhalation solution; pregnant or nursing women; patients of child-bearing potential not using highly effective methods of birth control; treatment with beta-blocker medication, oral or patch beta-adrenergics, systemic, i.e. oral or intravenous corticosteroids, LABA, tiotropium (Spiriva), investiga- 
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